The four-year agreement will support the team’s ongoing work on removing PFAS from soil. Photo via Rice University

A Rice University chemist James Tour has secured a new $12 million cooperative agreement with the U.S. Army Engineer Research and Development Center on the team’s work to efficiently remove pollutants from soil.

The four-year agreement will support the team’s ongoing work on removing per- and polyfluoroalkyl substances (PFAS) from contaminated soil through its rapid electrothermal mineralization (REM) process, according to a statement from Rice.

Traditionally PFAS have been difficult to remove by conventional methods. However, Tour and the team of researchers have been developing this REM process, which heats contaminated soil to 1,000 C in seconds and converts it into nontoxic calcium fluoride efficiently while also preserving essential soil properties.

“This is a substantial improvement over previous methods, which often suffer from high energy and water consumption, limited efficiency and often require the soil to be removed,” Tour said in the statement.

The funding will help Tour and the team scale the innovative REM process to treat large volumes of soil. The team also plans to use the process to perform urban mining of electronic and industrial waste and further develop a “flash-within-flash” heating technology to synthesize materials in bulk, according to Rice.

“This research advances scientific understanding but also provides practical solutions to critical environmental challenges, promising a cleaner, safer world,” Christopher Griggs, a senior research physical scientist at the ERDC, said in the statement.

Also this month, Tour and his research team published a report in Nature Communications detailing another innovative heating technique that can remove purified active materials from lithium-ion battery waste, which can lead to a cleaner production of electric vehicles, according to Rice.

“With the surge in battery use, particularly in EVs, the need for developing sustainable recycling methods is pressing,” Tour said in a statement.

Similar to the REM process, this technique known as flash Joule heating (FJH) heats waste to 2,500 Kelvin within seconds, which allows for efficient purification through magnetic separation.

This research was also supported by the U.S. Army Corps of Engineers, as well as the Air Force Office of Scientific Research and Rice Academy Fellowship.

Last year, a fellow Rice research team earned a grant related to soil in the energy transition. Mark Torres, an assistant professor of Earth, environmental and planetary sciences; and Evan Ramos, a postdoctoral fellow in the Torres lab; were given a three-year grant from the Department of Energy to investigate the processes that allow soil to store roughly three times as much carbon as organic matter compared to Earth's atmosphere.

By analyzing samples from the East River Watershed, the team aims to understand if "Earth’s natural mechanisms of sequestering carbon to combat climate change," Torres said in a statement.

The funds were awarded to Han Xiao, a scientist at Rice University.

Houston chemist lands $2M NIH grant for cancer treatment research

future of cellular health

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories.

Xiao will use the five-year grant to develop noncanonical amino acids (ncAAs) with diverse properties to help build proteins, according to a statement from Rice. He and his team will then use the ncAAs to explore the vivo sensors for enzymes involved in posttranslational modifications (PTMs), which play a role in the development of cancers and neurological disorders. Additionally, the team will look to develop a way to detect these enzymes in living organisms in real-time rather than in a lab.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement.

According to Rice, these developments could have major implications for the way diseases are treated, specifically for epigenetic inhibitors that are used to treat cancer.

Xiao helped lead the charge to launch Rice's new Synthesis X Center this spring. The center, which was born out of informal meetings between Xio's lab and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine, aims to improve cancer outcomes by turning fundamental research into clinical applications.

They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.